Bio-Path Holdings Inc is a clinical & preclinical stage oncology focused antisense drug development company utilizing novel technology achieving systemic delivery for specific protein inhibition for any gene product that is over-expressed in disease.
$6.84
As of 04/09/2021 IEX book CBOE book
2021 © Stock Market MBA, Inc.